These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 26317793)
1. Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma. Yang H; Li XD; Zhou Y; Ban X; Zeng TT; Li L; Zhang BZ; Yun J; Xie D; Guan XY; Li Y Oncotarget; 2015 Sep; 6(28):26079-89. PubMed ID: 26317793 [TBL] [Abstract][Full Text] [Related]
2. Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma. Li Y; Fu L; Li JB; Qin Y; Zeng TT; Zhou J; Zeng ZL; Chen J; Cao TT; Ban X; Qian C; Cai Z; Xie D; Huang P; Guan XY Gastroenterology; 2014 Jun; 146(7):1701-13.e9. PubMed ID: 24561231 [TBL] [Abstract][Full Text] [Related]
3. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy. Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013 [TBL] [Abstract][Full Text] [Related]
4. eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma. Liu T; Li R; Zhao H; Deng J; Long Y; Shuai MT; Li Q; Gu H; Chen YQ; Leng AM Oncotarget; 2016 Oct; 7(41):66851-66864. PubMed ID: 27588477 [TBL] [Abstract][Full Text] [Related]
5. Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c-Myc/microRNA-29b Axis. Bai HY; Liao YJ; Cai MY; Ma NF; Zhang Q; Chen JW; Zhang JX; Wang FW; Wang CY; Chen WH; Jin XH; Xu RH; Guan XY; Xie D Stem Cells; 2018 Feb; 36(2):180-191. PubMed ID: 29119708 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2. Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960 [TBL] [Abstract][Full Text] [Related]
7. EIF5A2 is a novel chemoresistance gene in breast cancer. Liu Y; Du F; Chen W; Yao M; Lv K; Fu P Breast Cancer; 2015 Nov; 22(6):602-7. PubMed ID: 24638963 [TBL] [Abstract][Full Text] [Related]
8. Cancer-associated fibroblasts mediated chemoresistance by a FOXO1/TGFβ1 signaling loop in esophageal squamous cell carcinoma. Zhang H; Xie C; Yue J; Jiang Z; Zhou R; Xie R; Wang Y; Wu S Mol Carcinog; 2017 Mar; 56(3):1150-1163. PubMed ID: 27769097 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of eukaryotic initiation factor 5A2 (EIF5A2) is associated with cancer progression and poor prognosis in patients with early-stage cervical cancer. Yang SS; Gao Y; Wang DY; Xia BR; Liu YD; Qin Y; Ning XM; Li GY; Hao LX; Xiao M; Zhang YY Histopathology; 2016 Aug; 69(2):276-87. PubMed ID: 26799253 [TBL] [Abstract][Full Text] [Related]
10. Sonic Hedgehog-GLI Family Zinc Finger 1 Signaling Pathway Promotes the Growth and Migration of Pancreatic Cancer Cells by Regulating the Transcription of Eukaryotic Translation Initiation Factor 5A2. Xu X; Liu H; Zhang H; Dai W; Guo C; Xie C; Wei S; He S; Xu X Pancreas; 2015 Nov; 44(8):1252-8. PubMed ID: 26465952 [TBL] [Abstract][Full Text] [Related]
11. Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy. Huang PY; Zeng TT; Ban X; Li MQ; Zhang BZ; Zhu YH; Hua WF; Mai HQ; Zhang L; Guan XY; Li Y BMC Cancer; 2016 Aug; 16(1):669. PubMed ID: 27549330 [TBL] [Abstract][Full Text] [Related]
12. Eukaryotic translation initiation factor 5A2 regulates the migration and invasion of hepatocellular carcinoma cells via pathways involving reactive oxygen species. Liu RR; Lv YS; Tang YX; Wang YF; Chen XL; Zheng XX; Xie SZ; Cai Y; Yu J; Zhang XN Oncotarget; 2016 Apr; 7(17):24348-60. PubMed ID: 27028999 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Chemotherapy Induces IL34 Signaling and Promotes Chemoresistance via Tumor-Associated Macrophage Polarization in Esophageal Squamous Cell Carcinoma. Nakajima S; Mimura K; Saito K; Thar Min AK; Endo E; Yamada L; Kase K; Yamauchi N; Matsumoto T; Nakano H; Kanke Y; Okayama H; Saito M; Neupane P; Saze Z; Watanabe Y; Hanayama H; Hayase S; Kaneta A; Momma T; Ohki S; Ohira H; Kono K Mol Cancer Res; 2021 Jun; 19(6):1085-1095. PubMed ID: 33674443 [TBL] [Abstract][Full Text] [Related]
14. The Opposing Function of STAT3 as an Oncoprotein and Tumor Suppressor Is Dictated by the Expression Status of STAT3β in Esophageal Squamous Cell Carcinoma. Zhang HF; Chen Y; Wu C; Wu ZY; Tweardy DJ; Alshareef A; Liao LD; Xue YJ; Wu JY; Chen B; Xu XE; Gopal K; Gupta N; Li EM; Xu LY; Lai R Clin Cancer Res; 2016 Feb; 22(3):691-703. PubMed ID: 26405196 [TBL] [Abstract][Full Text] [Related]
15. Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Yamasaki M; Makino T; Masuzawa T; Kurokawa Y; Miyata H; Takiguchi S; Nakajima K; Fujiwara Y; Matsuura N; Mori M; Doki Y Br J Cancer; 2011 Feb; 104(4):707-13. PubMed ID: 21206495 [TBL] [Abstract][Full Text] [Related]
16. N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of NSCLC cells to cetuximab through inhibition of eukaryotic translation initiation factor 5A2 activation. Wang X; Jiang R; Cui EH; Feng WM; Guo HH; Gu DH; Tang CW; Xue T; Bao Y Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1244-50. PubMed ID: 27097942 [TBL] [Abstract][Full Text] [Related]
17. Effects and mechanisms of FBXO31 on Taxol chemoresistance in esophageal squamous cell carcinoma. Lv L; Wang SC; Mo JY; Huang KL; Xu ML; Liu J Biochem Biophys Res Commun; 2022 Jan; 586():129-136. PubMed ID: 34839191 [TBL] [Abstract][Full Text] [Related]
18. Targeting beta1 integrin restores sensitivity to docetaxel of esophageal squamous cell carcinoma. Mori R; Ishiguro H; Kuwabara Y; Kimura M; Mitsui A; Tomoda K; Mori Y; Ogawa R; Katada T; Harata K; Fujii Y Oncol Rep; 2008 Dec; 20(6):1345-51. PubMed ID: 19020712 [TBL] [Abstract][Full Text] [Related]
19. Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells. Cao TT; Lin SH; Fu L; Tang Z; Che CM; Zhang LY; Ming XY; Liu TF; Tang XM; Tan BB; Xiang D; Li F; Chan OY; Xie D; Cai Z; Guan XY Carcinogenesis; 2017 Jan; 38(1):94-104. PubMed ID: 27879277 [TBL] [Abstract][Full Text] [Related]
20. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. Chen Q; Song S; Wei S; Liu B; Honjo S; Scott A; Jin J; Ma L; Zhu H; Skinner HD; Johnson RL; Ajani JA Oncotarget; 2015 Sep; 6(28):25883-96. PubMed ID: 26317542 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]